T he concept that the immune system can control tumor growth can be traced back to 1893 when William Coley used live bacteria as an immune stimulant to treat cancer. This natural protective mechanism of the human body to control cancer is now known to be elicited by key immune-checkpoint molecules, often present on cytotoxic T cells 1 . However, tumor cells can exploit these immune-checkpoint pathways as a mechanism to evade detection by the immune response, for example by altering the expression of key ligands on tumor cells such as PD-L1 and CD80/86, to inhibit the cytotoxicity activity of immune cells. Understanding the underlying mechanism by which cancer cells can 'molecularly cloak' themselves and remain hidden to immune surveillance is of great interest to cancer biology and provides the rationale design of therapeutic interventions. Although direct transcriptional control of inhibitory immune-checkpoint molecules by specific oncogenic pathways has been reported 2, 3 , post-transcriptional control may offer a fast, highly tunable mechanism to control the abundance of effector proteins guiding immune evasion of cancer cells. Yet, this level of regulation of the immune-checkpoint molecules remains largely uncharacterized.
T he concept that the immune system can control tumor growth can be traced back to 1893 when William Coley used live bacteria as an immune stimulant to treat cancer. This natural protective mechanism of the human body to control cancer is now known to be elicited by key immune-checkpoint molecules, often present on cytotoxic T cells 1 . However, tumor cells can exploit these immune-checkpoint pathways as a mechanism to evade detection by the immune response, for example by altering the expression of key ligands on tumor cells such as PD-L1 and CD80/86, to inhibit the cytotoxicity activity of immune cells. Understanding the underlying mechanism by which cancer cells can 'molecularly cloak' themselves and remain hidden to immune surveillance is of great interest to cancer biology and provides the rationale design of therapeutic interventions. Although direct transcriptional control of inhibitory immune-checkpoint molecules by specific oncogenic pathways has been reported 2, 3 , post-transcriptional control may offer a fast, highly tunable mechanism to control the abundance of effector proteins guiding immune evasion of cancer cells. Yet, this level of regulation of the immune-checkpoint molecules remains largely uncharacterized.
To study how oncogene cooperation directs immune-checkpoint deregulation, we focused on primary liver cancer, the second leading cause of cancer deaths worldwide 4 . Hepatocellular carcinoma (HCC) lacks effective cures except for early surgical intervention or liver transplantation, highlighting the urgent need for new therapeutic strategies. c-MYC, overexpression of which is commonly caused by genomic amplification, is widely amplified 5 and present in 70% of viral and alcohol-related HCC 6 and has a critical role in the malignant transformation of hepatocytes into HCC 7, 8 . Of all genetic alternations in HCC patients, there is an over-representation of pathways related to receptor tyrosine kinase (RTK) signaling, with ~22-37% of HCC patients having at least one alternation in genes associated to RTK/RAS/PI3K pathway
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We then crossed this c-MYC transgenic mouse to a well-established Cre-inducible, constitutively active KRAS G12D mouse that mimics notably enhanced downstream signaling of RTK 9, 10 , whereby liverspecific expression is achieved through Albumin-Cre-mediated recombination ( Supplementary Fig. 1d ,e). In this setting, MYC overexpression in the liver was not sufficient to drive cancer in vivo, whereas KRAS G12D and MYC (referred to here as MYC Tg ;KRAS G12D ) synergized to provoke a more aggressive tumor compared with the KRAS G12D alone (Fig. 1a) . This aggressive tumor was characterized by decreased tumor latency (Fig. 1a) , the simultaneous presence of intrahepatic cholangiocarcinoma and HCC (Fig. 1b) , as well as decreased survival. Notably, MYC Tg ;KRAS G12D mice showed a marked increase in metastasis in 90% of animals, compared with only 10% in KRAS G12D alone (Fig. 1c,d ). Metastasis occurred primarily in the lungs (Fig. 1d ), but could also be identified in lymph nodes ( Supplementary Fig. 1f ). These findings suggest that the barrier for primary and metastatic tumor development in KRAS G12D tumors is broken by MYC hyperactivation.
By characterizing the microenvironment of MYC
Tg
;KRAS G12D tumors, we observed a robust invasion of inflammatory cells in comparison to KRAS G12D alone (Fig. 1e) . Notably, MYC
;KRAS G12D -driven inflammatory cell infiltration is characterized by increased CD45+ leukocytes including neutrophils and macrophages ( Fig. 1f and Supplementary Fig. 1g-i ). The infiltration of inflammatory cells has been shown to enhance tumor angiogenesis, proliferation, metastasis, and therapy resistance 11 , and therefore may contribute to the aggressive phenotype of MYC Tg ;KRAS G12D -driven cancer. Notably, we also detected an increased infiltration of a cytotoxic, CD8+ T cell biased tumor-infiltrating lymphocytes ( Fig. 1g and Supplementary Fig. 1j ), which has a central role in anti-tumor immunity and tumor regression. However, despite the increased CD8+ T cell population that has been associated with an improved prognosis [12] [13] [14] , MYC Tg ;KRAS G12D -driven liver cancer progresses more aggressively. Based on these, we proposed that cancer cells with MYC and KRAS activation may escape immune surveillance and suppress the cytotoxicity of CD8+ T cells in the tumor microenvironment [15] [16] [17] [18] . This escape from immune surveillance may be a broader characteristic of MYC and KRAS-driven cancers 19 .
MYC and KRAS cooperation selectively alters gene expression at the translation level. We proposed that MYC and KRAS cooperate to drive unique gene expression programs in cancer cells to evade immune-destruction and develop metastasis. To survey the genome-wide gene expression at both the transcription and translation level in an unbiased manner, we first carefully micro-dissected primary liver tumor nodules in MYC Tg ;KRAS G12D and KRAS
G12D
mice as well as wild-type livers as controls. We deep-sequenced total mRNAs and ribosome-protected mRNA fragments using ribosome profiling 20 to generate genome-wide transcriptional and translational landscapes, respectively ( Supplementary Fig. 2 ). Applying the framework of the generalized linear model, a linear regression was performed to the normalized read counts, as a function of sample type variables ('WT' , 'KRAS G12D ' , or 'MYC Tg ;KRAS G12D '). Here, the coefficient of sample type variables (that is, 'MYC Tg ;KRAS G12D ' over 'KRAS G12D ') is a measurement of corresponding differential gene expression. The transcriptional expression profile in the MYC Tg ;KRAS G12D murine model of HCC exhibits significant similarities to human HCC ( Supplementary Fig. 3 ). Human HCC samples harboring both MYC amplification and RTK signaling activation ( Supplementary Fig. 3a ) possess a gene expression pattern that strongly correlated with that of our MYC Tg ;KRAS G12D murine HCC ( Supplementary Fig. 3b,c) . These findings support that our GEM model is a highly relevant and suitable model for studying human HCC. When the global transcriptome (RNA-Seq) and translatome (Ribo-Seq) profiles were directly compared, we observed that activation of KRAS alone results in a coordinated change in RNA-Seq and Ribo-seq compared with wild-type hepatocytes (Fig. 2a, Supplementary Fig. 4 , and Supplementary Table 1 ).
In the context of both MYC and KRAS activation, we detected few statistically significant changes at the mRNA level compared with KRAS activation alone (11 down-and 13 upregulated transcripts with P adj < 0.1 and |log 2 FC| > 2 in RNA-Seq) (Fig. 2a and  Supplementary Table 2 ), but we observed changes in ribosome footprints for a subset of transcripts (130 down-and 339 upregulated transcripts with P adj < 0.1 and |log 2 FC| > 2 in Ribo-Seq) (Fig. 2a, Supplementary Fig. 4 , and Supplementary Table 2) . Further validation will be required to determine whether these Ribo-Seq changes are a result of a combination of changes in transcription and translation or translation/transcription alone ( Supplementary  Fig. 4 ). Nevertheless, these findings raise the possibility that in the context of two cooperating oncogenes, the translational profile of gene expression is distinct. ;KRAS G12D tumors compared with KRAS G12D (P adj < 0.1 and log 2 FC > 2 in Ribo-Seq). This revealed several significantly enriched gene ontology categories (P adj < 0.05) that were grouped into major functional clusters including: defense response, cell activation, chemotaxis, cell cycle process, and cellular response to chemical stimulus (Fig. 2b and Supplementary Table 3) . Notably, in the cell activation cluster, we found the immune-checkpoint gene Cd274 encoding the mouse ortholog of PD-L1 ( Fig. 2b and Supplementary  Fig. 5 ). Despite PD-L1 mRNA being relatively equally induced in both KRAS G12D (Supplementary  Table 2 ), suggesting possible translational upregulation of the gene. PD-L1 is a transmembrane protein expressed on tumor cells that is a ligand of the immune-checkpoint receptor programmed death-1 (PD-1) on T cells. PD-L1/PD-1 interaction leads to the negative regulation of T cell proliferation, migration and activation, allowing tumor cells to evade the anti-tumor immune response 21 , which matches the phenotype of the MYC Tg ;KRAS G12D tumor. Thus, we suggested that the translational upregulation of PD-L1 by MYC and RAS cooperation may lead to immune evasion and the aggressive cancer phenotype in MYC Tg ;KRAS G12D mice. As PD-L1 is also widely expressed on tumor-infiltrating immune cells such as T cells and some myeloid cells 22, 23 , we first confirmed HCC tumor-specific expression of PD-L1 using immunofluorescence-based co-staining of MYC Tg -expressing liver cells with PD-L1 (Fig. 2c) . Consistent with our ribosome-profiling analysis showing an approximate fivefold increase in ribosome footprints at the PD-L1 mRNA in MYC Tg ;KRAS G12D compared with KRAS G12D (Supplementary Fig. 5 ), there is a corresponding fourfold increase of PD-L1 protein abundance observed in MYC Tg ;KRAS G12D tumors by immunofluorescence (Fig. 2c) , and this occurred independently of changes in mRNA amounts (Fig. 2d) .
MYC reprograms PD-
To Fig. 6a-c ). Noteworthy and consistent with previous studies, PD-L1 protein expression is typically assessed by flow cytometry [24] [25] [26] [27] . Using the in vitro culturing of these cell lines, we specifically observed an increase in protein abundance of PD-L1 by flow cytometry in the MYC Tg ;KRAS G12D background with no significant difference at the mRNA level ( Fig. 2e and Supplementary Fig. 6d ), which also demonstrates that the upregulation of PD-L1 in MYC Tg ;KRAS G12D tumor is a result of primary oncogenic cooperation, rather than a reaction to anti-tumor immunity from the tumor microenvironment. ;KRAS G12D cell lines, n = 3 independent experiments. Inset highlights the polysomal fractions (7) (8) (9) (10) (11) (12) . Right: qualitative PCR with reverse transcription (RT-qPCR) analysis of PD-L1 mRNA levels in fractions, percentages of PD-L1 mRNA distributed in each fraction against total PD-L1 mRNA are shown. Two-sided t test. 
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MYC at the protein level ( Supplementary Fig. 6e-g ) without affecting their mRNA expression ( Supplementary Fig. 6h ).
Although G12D liver tumor cells, we examined its distribution in polysomes (translationally active ribosome fractions) on sucrose gradient fractionation (Fig. 2f ). There is a higher percentage of PD-L1 mRNA accumulated in the translationally inactive free subunit and monosome fractions (fractions 2-6) in KRAS G12D liver tumor cells ( Fig. 2f and Supplementary Fig. 7a ), revealing that the translation of PD-L1 mRNA is relatively suppressed in KRAS G12D cells. However, in MYC Tg ;KRAS G12D cells there was a significant shift of PD-L1 mRNA, but not the GAPDH control mRNA, towards the translationally active, polysome fractions (fractions 8-11) ( Fig. 2f and Supplementary Fig. 7a,b) , showing that the control of PD-L1 expression is at the level of mRNA translation in MYC Tg and KRAS G12D cooperation-driven cancer. This is consistent with the observation made in fresh frozen human HCC tumor samples ( Supplementary Fig. 8a ,b), where we observed a significant correlation between MYC amounts and PD-L1 protein abundances (Fig. 2g) , whereas PD-L1 mRNA expression was not correlated (Fig. 2h ).
MYC enhances PD-L1 translation through bypassing upstream open reading frame (uORF)-mediated translational repression.
We next sought to address the mechanism by which PD-L1 mRNA is inefficiently translated in KRAS G12D liver tumor cells, but becomes translationally activated in MYC Tg ;KRAS
G12D
. The translation of mRNAs is highly controlled by the 5′ untranslated region (5′ UTR), which can contain several regulatory elements including complex structures as well as sequence-specific RNA elements 28 .
To explore how PD-L1 is translationally regulated, we analyzed the 5′ UTR sequence of the PD-L1 mRNA. Notably, the mouse PD-L1 mRNA contained three putative uORFs, one of which initiates from an upstream AUG (uAUG), and the other two from non-canonical upstream CUG start codons (uCUG) that partially overlaps with the main PD-L1 ORF (Fig. 3a) . To molecularly validate the engagement of the ribosome on these uORFs, we performed a toeprint assay in KRAS G12D and MYC
Tg
;KRAS G12D cell lysates to directly visualize ribosome footprints on the upstream initiation codons of an in-vitro-transcribed PD-L1 5′ UTR reporter. We detected that, in KRAS G12D cell lysate, ribosome footprints are preferably observed at the uAUG and the proximal uCUG (the uCUG near the main ORF), rather than the main AUG (Fig. 3b , RNA loading controls in Supplementary Fig. 9a ). Mutating the uCUG in this reporter significantly abolished ribosome recognition of uCUG upstream start codons ( Supplementary Fig. 9b ). On the contrary, in MYC Tg ;KRAS G12D cell lysates, the major ribosome footprints occur at the main AUG, compared to the uAUG or uCUG (Fig. 3b) .
Although recent studies have identified putative uORFs genome-wide 29 , little is known about the functional contribution of uORF-mediated regulation, particularly in the context of cancer development and the regulation of the immune-checkpoint molecules. To understand whether the uORFs in the 5′ UTR of PD-L1 have a significant role in PD-L1 translational control, we transfected the full-length PD-L1 5′ UTR upstream of a luciferase reporter in KRAS G12D and MYC
;KRAS G12D cells. We observed that the reporter activity of wild-type PD-L1 5′ UTR in MYC Tg ;KRAS G12D cells was significantly higher compared with that in KRAS G12D cells (Fig. 3c) . To characterize the functionality of these uORFs, we mutated the start codons of individual uORFs (Fig. 3d) . Notably, disrupting either the uCUG near the main ORF (uCUG(proximal)) or the uAUG in KRAS G12D cells increased the reporter activity by > 100%, whereas mutating the uCUG apart from the main ORF (uCUG(distal)) had no effect (Fig. 3d) . This increase in the reporter activity on proximal uCUG mutation was less significant (~25%) in MYC Tg ;KRAS G12D cells (Fig. 3e) . In addition, mutating the stop codon of the uORF, which placed the proximal uCUG in frame with the main ORF, led to a significant increase in reporter activity in KRAS G12D cells (Supplementary Fig. 9c ). We also designed a vector where the uCUG is the only initiating codon that can produce a full-length flag-tagged PD-L1 protein (uCUG-PD-L1-FLAG). In this setting, we observed the expression of a full-length flagged-PD-L1 protein in KRAS G12D cells (Fig. 3f) , further validating the functionality of the uCUG. Moreover, mutating both the uCUG(proximal) and the uAUG led to further enhanced reporter activity (300% increase) (Fig. 3d) . These results indicate that there are two functional uORFs (uORF_1 and uORF_3 mediated by uAUG and the proximal uCUG, respectively) in mouse PD-L1 5′ UTR that act in an additive manner to suppress downstream main ORF translation.
To further characterize the functional significance of these two uORFs in regulating endogenous PD-L1 translation, we used CRISPR/Cas9 genome editing to generate KRAS G12D -derived tumor cell lines in which the proximal uCUG (Fig. 3g) or the uAUG ( Supplementary Fig. 9d ) in the PD-L1 mRNA 5′ UTR is disrupted. Disruption of the uCUG or the uAUG start codon led to significantly enhanced protein abundance of endogenous PD-L1 compared to the non-mutated parental clone ( Fig. 3g and Supplementary Fig. 9d ), with no effect on PD-L1 mRNA amounts ( Supplementary Fig. 9e ). Dependence of these non-canonical uORFs highlights their key role in control of PD-L1 expression at the translation level. Similarly, the human PD-L1 5′ UTR also contains uCUG start codon uORFs, where the initiation ribosome footprints on these uORFs can be detected in previously published ribosome-profiling datasets carried out in the presence of lactimidomycin 30 , which stalls ribosomes on initiating codons ( Supplementary Fig. 9f ). By mutating the uCUGs in the human PD-L1 5′ UTR, we observed an 100% increase in the translation of the downstream main ORF (Fig. 3h) , suggesting that similar to mouse, human PD-L1 translation is also controlled by uORFs.
An outstanding question is how PD-L1 uORF-mediated translation repression is bypassed in MYC Tg ;KRAS G12D cells. We observed that MYC Tg ;KRAS G12D clones had significantly higher eIF2α phosphorylation amounts compared with our KRAS G12D clones (Fig. 3i ). eIF2α is a key component of the eIF2 ternary complex [31] [32] [33] that when phosphorylated facilitates the bypass of uORFs, thereby favoring translation of the main ORF. When we treated MYC Tg ;KRAS G12D cells with integrated stress response inhibitor (ISRIB), a compound selectively reverses the effects of eIF2α phosphorylation 34, 35 , the abundance of PD-L1 protein in MYC Tg ;KRAS G12D cells was markedly downregulated (Fig. 3j) , whereas PD-L1 mRNA remained unchanged ( Supplementary Fig. 10 ). These results suggest, at least in part, a functional role for eIF2α phosphorylation in bypass of uORFs. Altogether, several orthogonal lines of evidence demonstrate that MYC elevates PD-L1 protein abundance through relieving the inhibition of PD-L1 mRNA translation mediated by functional, non-canonical uORFs. (Fig. 2c) , whether the increased PD-L1 expression and subsequent immune evasion are responsible for the cancer metastatic potential remains unclear. To this end, we orthotopically injected two individual uCUG mutant KRAS G12D clones containing a mutation of the uORF that stimulates PD-L1 translation (KRAS G12D Mut clone 1 and 2), into the subcapsular region of the median liver lobe of mice ( Supplementary  Fig. 11a ). Noteworthy, we confirmed that this immunocompetent C57BL/6 orthotopic model was able to recapitulate disease progression in a similar manner as our GEM models: C57BL/6 mice ;KRAS G12D cell lines. Two-sided t test, n = 3 independent experiments. d, Percentage increase in the 5′ UTR reporter activity of mouse PD-L1 uORF-luciferase with point mutations (CU'G' to CU'C' or AU'G' to AU'C') in the three upstream start codons over that with wild type, in KRAS G12D cells. Two-sided t test, n = 3. e, 5′ UTR reporter activity of mouse PD-L1 uORF-luciferase with and without a point mutation (CU'G' to CU'C') in the proximal uCUG start codon, in KRAS G12D ) in the luciferase activity of the uCUG mutation compared with wild type (WT) were shown. f, Upper: constructs for expressing a FLAG-tagged PD-L1 with 'AUG' start codon mutation (A'UGA' to A' A') (uCUG-PD-L1-FLAG). Lower: western blot of FLAG and GAPDH in KRAS G12D cell lines after 48-h transfection, n = 3 independent experiments. g, Upper: mouse PD-L1 5′ UTR exon and intron DNA sequence of the wild-type (WT) and uCUG mutation KRAS G12D clonal cell line are shown. PAM region (AGG) is highlighted in red, which spans the 5′ UTR exon and intron; CRISPR target region that against the 5′ UTR exon is labeled in blue. 1 nucleotide (nt) insertion (CTG to C"T"TG) is detected in the uCUG start codon after the CRISPR/Cas9 editing. Lower: relative PD-L1 abundance in wild-type and two-mutation clonal cell lines determined by flow cytometry. Two-sided t test, n = 3 independent experiments. h, 5′ UTR reporter activity of human PD-L1 uORF-luciferase with and without point mutations (CU'G' to CU'C') in the uCUG start codons in SNU-449 human HCC cell line (wild type, WT). Two-sided t test, n = 3 independent experiments. i, Western blot of p-eIF2α , eIF2α and GAPDH in KRAS (Fig. 4a) , aggressive immune infiltration in the liver (Fig. 4b and Supplementary Fig. 11b ), increased PD-L1 abundance ( Supplementary Fig. 11c ), and increased metastatic potential (Fig. 4b,c and Supplementary Fig. 11d ) when compared with those injected with KRAS G12D cells. In this system, KRAS G12D cells only developed primary tumors with no metastasis (Fig. 4c and Supplementary Fig. 11d) . Notably, 44.4 and 50% of animals injected with the two KRAS G12D uORF mutant clones, respectively, developed metastasis (Fig. 4c,d) . These results show that increasing the translation of PD-L1 in KRAS G12D uORF mutant tumor cells is sufficient to facilitate metastasis, suggesting that the activity of PD-L1 on inhibiting immune surveillance is a key determinant of metastatic potential and cancer aggressiveness. Therefore, to delineate the contribution of T cell surveillance on metastases and survival, we injected MYC Tg ;KRAS G12D and KRAS G12D cells into athymic nude mice that lack functional T cells. Ablation of T cells in nude mice ameliorated the difference in the survival rates of KRAS G12D and MYC
;KRAS G12D HCC-injected mice (Fig. 4e) . Both KRAS
G12D
and MYC
Tg
;KRAS G12D HCC-injected athymic nude mice were able to 
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develop pulmonary metastases (Fig. 4f) , suggesting that the T cell immune surveillance normally restrains metastasis formation in KRAS G12D -derived tumors.
eFT508, a potent clinical translation inhibitor, dramatically downregulates PD-L1 protein abundance.
Given the finding that a new layer of translational control guides PD-L1 expression, which is important for tumor development, we sought to design a rational pharmacological approach to target PD-L1 translation. Although pharmacological agents that target the core translation machinery itself may induce unwanted toxicity, targeting their post-translational modifications may offer a more favorable therapeutic window. In this respect, it is known that phosphorylation of the main capbinding protein, eIF4E at Serine 209, positively regulates the oncogenic activity of eIF4E and promotes specific mRNA translation 36, 37 , whereas mutating the eIF4E phosphorylation site in knock-in mice has no effect on organismal development or physiology 36 . Similarly, ablation of the kinases responsible for phosphorylating eIF4E, mitogen-activated protein kinase interacting kinase 1 and 2 (MNK1/2), has proven to be dispensable for organismal life and the resulting mice do not show any discernible phenotypes 38 .
MYC
Tg
;KRAS G12D cells or liver tumors do not possess higher eIF4E phosphorylation than KRAS G12D alone ( Supplementary Fig. 12a, b ), yet given the selective increase in the translational oncogenic program in MYC
;KRAS G12D cells, we reasoned that these tumors may be more sensitive to inhibitors of translation. Thus, to determine whether increased PD-L1 translation can be exploited therapeutically, we used eFT508: a potent and highly selective dual MNK1/2 inhibitor 39 , now in phase 2 clinical trials (NCT02937675, NCT02605083 and NCT03258398). eFT508 is considerably more potent than other reported MNK inhibitors both biochemically (MNK1 and MNK2, 2.4 and 1 nM, respectively) and in cells inhibiting phosphorylation of eIF4E (6.5 nM). Moreover, eFT508 has exceptional kinome selectivity (tested against > 400 kinases) relative to reported MNK inhibitors (the nearest kinase is inhibited approximately 100-fold weaker than MNK1 or MNK2). In addition, eFT508 has excellent drug-like properties (MW 340, protein binding ~50%, logD = 2.7, Caco2 A-B/B-A 15/5, excellent multi-species oral PK) 39 . In liver tumors, eFT508 efficiently eliminated eIF4E phosphorylation ( Supplementary Fig. 12a ) without affecting global protein synthesis ( Supplementary Fig. 12c) . At first, we tested the effects of eFT508 on PD-L1 expression in MYC Tg ;KRAS G12D cells. Notably, inhibiting eIF4E phosphorylation by eFT508 resulted in significant and selective downregulation of MYC Tg ;KRAS
G12D
-induced PD-L1 protein abundance (Fig. 5a ), but not mRNA expression (Fig. 5b) ; similar effects were also detected for several other translational targets upregulated in MYC Tg ;KRAS G12D cells ( Supplementary Fig. 12d-f ). On the contrary, eFT508 had limited additional effects in reducing PD-L1 protein abundance in KRAS G12D cells where PD-L1 translation is suppressed (Supplementary Fig. 12g ). We further found that KRAS G12D cells harboring mutations in the uAUG and uCUG uORFs of PD-L1 (KRAS G12D uAUG + uCUG_mut) exhibited reduced PD-L1 protein expression by eFT508 ( Supplementary Fig. 12h ), suggesting that the enhanced translation of PD-L1 can sensitize cells to this translation inhibitor. However, we cannot at present exclude a potentially more direct effect of eIF4E phosphorylation on uORFmediated translational repression. Moreover, the effects of eFT508 on PD-L1 translation can be mirrored genetically in eIF4E phosphorylation-ablated (Eif4e S209A/S209A ) mice 36 that show a 50% decrease in PD-L1 protein expression compared with wild type when livers of these animals are transfected with MYC and KRAS G12D in vivo ( Fig. 5c and Supplementary Fig. 12i Supplementary Fig. 12j ), doubled the survival time of C57BL/6 mice bearing MYC Tg ;KRAS G12D tumors (Fig. 5d) , and prevented lung metastasis formation (Fig. 5e) . Moreover, eFT508 led to a marked inhibition of eIF4E phosphorylation and 50% reduction in PD-L1 abundance in vivo (Fig. 5f ), which recapitulated our in vitro findings. Of note, eFT508 had no effect in mice bearing KRAS G12D tumors (Fig. 5g) , suggesting that although more aggressive, MYC Tg ;KRAS G12D tumors are more sensitive to eFT508 treatment, as they rely on PD-L1 translation for their progression. The possibility of the presence of an HA model antigen derived from the HA-tag linked to MYC transgene does not influence the immune microenvironment ( Supplementary Fig. 13a,b) nor the sensitivity to eFT508 treatment (Supplementary Fig. 13c ).
To further address whether inhibiting the PD-1/ PD-L1 functional complex could mimic the anti-tumor effect of eFT508, we treated the MYC Tg ;KRAS G12D orthotopic model with monoclonal antibodies against PD-1. Treatment with anti-PD-1 resulted in a significant increase in survival (Fig. 5h) , suggesting that targeting the PD-1/PD-L1 axis can markedly reduce the aggressiveness of MYC Tg ;KRAS G12D tumors. However, unlike the monoclonal antibodies against PD-L1 that also target and may kill immune cells in the tumor microenvironment that express PD-L1 40, 41 , eFT508 has a high selectivity against the PD-L1 protein on tumor cells, but not the infiltrated myeloid cells, liver-resident macrophages, and T cells (where PD-L1 expression is relatively low in our tumor model) ( Supplementary Fig. 14a,b) . Furthermore, eFT508 treatment resulted in a significant increase in cytotoxic CD8+ T cells compared with untreated tumors (Fig. 5i ) that were positive in cytotoxic anti-tumor activity as assessed by surface CD107A abundance 42 ( Fig. 5j) . Together, these findings reveal a key molecular underpinning of the immune response in acquiring metastatic potential, the leading cause of cancer lethality, and highlight that oncogene-mediated translational control of the immune checkpoint is effectively targeted with eFT508 specifically in tumor cells without affecting immune cells, maximizing the anti-tumor effect.
Discussion
Oncogenes widely manipulate many diverse gene expression programs to direct cancer progression. Given the fact that we have profiled two end-stage tumor types (KRAS G12D and MYC
Tg
;KRAS G12D tumors), during the course of their evolution, similar transcriptome profiles may have been co-opted and are consistent with Myc hyperactivation in fully developed Ras tumors. Instead, a more profound remodeling of gene expression at the step of translation control offers unique gene regulatory programs to selectively synthesize effector proteins in unique stages of cancer development, for example, to shape the tumor microenvironment (Fig. 2b) . The broader implication of our data is that translational regulation of the immune regulators facilitates tumor cells evasion from immune attack to promote tumor progression and metastasis, and this regulation is not typically detected by standard methodologies that profile cancer cells (that is, genomics and transcriptomics). In particular, although a potent uORF embedded in the PD-L1 5′ UTR serves as the main obstacle for the efficient translation of PD-L1 mRNA, this mechanism leaves a 'backdoor' for specific oncogenes, such as MYC, to re-activate PD-L1 translation at least in part by hijacking the phospho-eIF2α dependent adaptive stress pathway, which has been previously linked to the oncogenic activity of MYC 43 . Cancer cells may use this unique mechanism to more rapidly synthesize PD-L1 protein (compared with transcriptional control), in response to tumor immune environment changes, allowing for tumor progression and metastasis. It is also important to note that genetic alterations in regulatory elements in the 3′ untranslated Articles NATuRE MEDICINE region of PD-L1 increase PD-L1 expression 44 and it will be interesting to determine the interplay between translation control and mRNA stability of this key checkpoint protein. In this respect, a selective, clinically relevant translational inhibitor, eFT508, exhibits remarkable sensitivity when the translation of the immune-checkpoint protein is hyperactive. In addition, while this manuscript was 
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in press, a recent study has shown that components of the translation initiation complex, eIF4F, can also affect PD-L1 expression through the translational upregulation of STAT1, a transcription factor controlling PD-L1 expression 45 . Together with our work, this suggests that key immune-checkpoint proteins can be regulated by translation factors at many levels and that translation inhibitors may serve as important drugs for immunotherapies. In the context of liver cancer, our findings are significant as HCC is a major cause of cancer death worldwide with surgical resection as the only means to manage the disease, yet most patients are not suitable for surgery because of poor hepatic reserve and metastatic lesions. Furthermore, as the amplification and activation of MYC and RAS are among the most frequent lesions that cooperate in many human cancers 19, 46, 47 , translational control of the immune checkpoint is likely to be more widespread in many cancer types.
It remains poorly understood why only a fraction of cancer patients respond to immune-checkpoint antibody blockade, and resistance to immune-checkpoint inhibitors has been reported in cancer patients 48 . With respect to our ribosome-profiling data, besides PD-L1, there are several other key factors or pathways involved in cell cycle regulation, tumor cell motility and immune response that are upregulated by Ribo-Seq in tumors with MYC hyperactivation ( Supplementary Figs. 5 and 6 ), which are also effectively targeted by the translation inhibitor eFT508 ( Supplementary  Fig. 12 ). Therefore, selective inhibitors of mRNA translation, such as eFT508, may have the potential to both enhance anti-tumor immune response and inhibit cancer progression and metastasis, offering a therapeutic approach that could improve therapeutic efficacy over existing checkpoint inhibitors and could be further combined to achieve beneficial outcomes.
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Methods
Mice.
A modified pCAGEN vector 49 containing PmeI sites flanking the CAG promoter 50 and rabbit beta-1 globin gene polyadenylation sites was used to as the backbone of the transgenic vector. Cloning of a Lox-STOP-Lox element 51 , N-terminal HA-epitope tagged c-MYC (human), encephalomyocarditis virus internal ribosome entry site 52 , and palmitoylated-eGFP 53 was performed to insert these sequences in the multi cloning site located between the CAG promoter and the downstream beta-1 globin gene untranslated sequences containing polyadenylation sites to generate a Cre-activateable bicistronic mRNA capable of simultaneous expression of HA-tagged MYC and palmitoylated GFP in a wide array of cells and tissues. MYC Tg mice were created via pronuclear injection of the purified PmeI digested fragment containing the transgene sequence into C57Bl/6 zygotes by the Gladstone Institutes transgenic core facility. Our MYC Tg mice has a similar MYC overexpression range to human HCC. The LSL-KRAS G12D mouse (a point mutation endogenous KRAS locus) was purchased from The Jackson Laboratory, and mice with liver-specific KRAS G12D expression (Alb Cre; KRAS G12D ) were generated. In vivo sample preparation. Mouse liver tumors were micro-dissected immediately after animal euthanization. Liver perfusion (with ice-cold PBS containing 10 mg ml −1 cycloheximide). Wild-type liver or the micro-dissected tumors were snap frozen in liquid nitrogen, followed by grounding with mortar and pestle. Tumor was resuspended in the lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 15 mM MgCl 2 , 100 μ g ml −1 cycloheximide, 1 mM DTT, 0.5% Triton X-100, 0.1 mg ml −1 heparin, 8% glycerol, 20 U per ml TURBO DNase, × 1 Combined Protease and Phosphatase Inhibitor).
Deep-sequencing library preparation. The ribosome-profiling analysis was carried out as described previously 54 . Briefly, after removing the nuclei and mitochondria, lysate was treated with RNase A/T1 mix (0.5 mg RNase A (Ambion, AM2272) and 1,000 U RNase T1 (Life Technologies, 2280)) to digest mRNAs that are not protected by the ribosome. The digestion was stopped by adding SUPERase-In RNase Inhibitor (20 U per μ l, Ambion, AM2696), followed by centrifuging to pellet ribosomes. Ribosome-protected fragments were purified by TRIzol, and two biological replicates were performed for each type of Ribo-Seq and all Ribo-Seq libraries (three biological replicates for wild-type liver).
Analysis of RNA-Seq and Ribo-Seq libraries.
A layered alignment was performed to first discard reads mapping to mouse ribosomal RNA (rRNA) sequences using Burrows-Wheeler Aligner 55 . Non-rRNA reads were then aligned against the mouse transcriptome (GRCm38 build 76) using RSEM 56 and bowtie2 57 . Reads were aligned strand-specifically to exclude anti-sense or other non-transcript reads. For each gene, total number of ribosome-protected fragments and RNA reads were counted and fed into the downstream analysis. A minimum of two counts per million in at least two Ribo-Seq libraries was used as a cutoff to filter out lowly expressed genes, following the guideline 58 . Differential gene expression analyses were performed using the limma package 59 with voom method 60 . Briefly, the effective library size of each deep-sequencing library was calculated and raw read count data were normalized by the trimmed mean of M values method 61 . Normalized read counts were reported in Supplementary Tables 1 and 2 . Variancemean relationship in count data was estimated using the voom method 60 and differential gene expression was tested using a model of negative binomial distribution. A linear regression was performed to the normalized read counts, as a function of sample type variables ('WT' , 'KRAS ') is a measurement of corresponding differential gene expressions. P values were adjusted using the Benjamini-Hochberg procedure for multi-testing, and these adjusted P values (P adj or false discovery rate) were reported for each gene in Supplementary Data. To visualize the deep-sequencing datasets, sequencing reads were aligned to the mouse genome (GRCm38) using the STAR RNA-Seq aligner 62 , and imported into the Integrative Genomics Viewer 63 . For the comparison of the similarity of human liver cancer and mouse liver cancer: human liver hepatocellular carcinoma and normal liver samples were based on data generated by The Cancer Genome Atlas Research Network (http://cancergenome.nih.gov/). Raw estimated number of reads that aligned to each transcript were obtained for 370 primary tumors and 50 normal liver samples from FireBrowse (http://firebrowse.org/). Differential gene expression analyses were performed similar as for the mouse samples. Here, a linear regression was performed to the normalized read counts, as a function of sample type variables ('primary tumor' or 'normal'). The coefficient of sample type variables ('primary tumor' over 'normal') is a measurement of differential gene expressions. P values were adjusted using the Benjamini-Hochberg procedure for multi-testing.
Gene functional analyses and visualization. Gene Ontology enrichment and clustering analysis was carried out using ClueGO 64 for genes that are upregulated in Ribo-Seq comparing MYC Tg ;KRAS G12D to KRAS G12D (P adj < 0.1 and log 2 FC > 2).
The following parameters were used: Reference set: all genes analyzed; Enrichment: right-sided hypergeometric test, P value adjustment: Benjamini-Hochberg adjustment. Enriched gene ontology terms were then grouped using Kappa statistics with leading group term on the basis of the highest statistical significance. Protein interaction networks were retrieved from STRING v.10.0 database 65 and imported into Cytoscape 66 for visualization. Each node represents a gene and edges show protein-protein association with width proportional to the association score. Disconnected nodes were removed from the plot for simplicity.
Plasmids. PD-L1 5′ UTR was synthesized and cloned into the HindIII and NcoI sites of pGL3-SV40 control vector (Promega). CUG and STOP mutations were carried out using site-direct mutagenesis. PD-L1 5′ UTR, CDS and 3′ UTR fused with a FLAG sequence were amplified and cloned into murine stem cell virus backbone vector. CDS start codon ATG deletion and frame shift ('TG' removal from ' ATG') were generated by site-direct mutagenesis. Human MYC, a T2A peptide sequence and KRAS G12D were together cloned into a murine stem cell virus backbone vector. Sequences were based off the NCBI database.
Immunofluorescence. Liver and lung tissues were dissected from mice and fixed in 10% formalin overnight at 4 °C. Tissues were subsequently dehydrated in ethanol at room temperature, mounted into paraffin blocks and sectioned at 5 μ m. Specimens were de-paraffinized, rehydrated, and antigen unmasking was performed as previously described 54 . The sections were then incubated in 5% goat serum, 1% BSA in tris-buffered saline for 1 h at room temperature. Primary antibodies were diluted 1:50-1:500 in blocking solution and incubated on sections overnight at 4 °C. Specimens were incubated with the appropriate Alexa 488 and 594 labeled secondary (Invitrogen) at 1:500 for 2 h at room temperature after washing, followed by mounting with DAPI Hardset Mounting Medium (Vector Lab). Zeiss AxioImager M1 microscope was used to image. Individual cells were quantified for mean fluorescence intensity using the Axiovision (Zeiss, Release 4.8) densitometric tool.
H&E staining. Paraffin-embedded liver and lung specimens were de-paraffinized and rehydrated, and stained with hematoxylin (Thermo Scientific), followed with washes with water. An incubation in differentiation RTU (VWR) and two washes with water followed by two 70% ethanol washes were performed. The samples were then stained with eosin (Thermo Scientific) then dehydrated with ethanol followed by CitriSolv (Fisher). Slides were mounted with Cytoseal XYL (Richard Allan Scientific). 
Sucrose gradient fractionation. KRAS G12D and MYC
Tg
;KRAS G12D cells were treated with 0.1 mg ml −1 Cycloheximide for 5 min, before lysing in 300 μ l of lysis buffer (20 mM Tris pH 7.5, 200 mM NaCl, 15 mM MgCl 2 , 1 mM DTT, 1% Triton X-100, 0.1 mg ml −1 cycloheximide, 200 U per ml RNasin (Promega)). Nuclei and membrane debris was then removed by centrifuging at 10,000g, for 5 min. The lysate was loaded onto a sucrose gradient (10-50% sucrose(w/v), 20 mM Tris pH 7.5, 100 mM NaCl, 15 mM MgCl 2 ) and centrifuged in a SW41Ti rotor (Beckman) for 2.5 h at 38,000 r.p.m. at 4 °C. Fractions were collected by density gradient fractionation system (Teledyne ISCO).
qPCR. RNA was isolated using TRIzol (Invitrogen) purification using PureLink RNA Mini Kit (Thermo Fisher, 12183018). RNAs were converted into cDNAs using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). cDNAs were diluted 1 to 10, and used for SYBR green detection RT-qPCR assay. Primers were used at 250 nM per reaction. Cd274 F 5′ -AGTCTCCTCGCCTG CAGATA, Cd274 R 5′ -AGTAAACGCCCGTAGCAAGT. Gapdh F 5′ -CAATGA Intrahepatic metastatic HCC graft implantation and drug treatment. Ex vivo cultures of primary, single-clone cell lines from individual liver tumors were derived from one Alb-Cre; KRAS G12D and one Alb-Cre; MYC Tg ;KRAS G12D mice. HCC cells described above were trypsinized, counted and 5 × 10 5 of cells were injected into the subcapsular region of the median liver lobe of C57BL/6 mice. Analgesics including bupivacaine and buprenorphine were given to the mice, while meloxicam was not given as it may have an effect on the tumor immune microenvironment. Primary liver tumor formation was detected at day 4. Over 70% of the mice successfully develop lung metastasis at days 12-18. Mice were treated daily 7 d post-injection of tumor cells with 10 mg kg −1 of eFT508 or vehicle control through oral gavage.
Statistics. Data were represented as mean ± s.d. Sample sizes were chosen on the basis of previous literature, or decided by using a power analysis (power/sample size calculator) on the basis of pilot experiments that provided an estimate of effect size. For in vivo experiments in mice, an n = 4 was the minimum amount used. Data were analyzed and statistics performed in Microsoft Excel and/or GraphPad Prism6. A two-tailed, unpaired Student's t test was used for pair-wise comparison. For correlation analysis, a two-sided Pearson's correlation test was used. For survival analysis, a log-rank test or Wilcoxon rank sum test was used. P < 0.05 was considered significant, and the exact P values are indicated in the figures.
Ethical compliance. All experiments involving live vertebrates performed at UCSF were done in compliance with ethical regulations approved by the UCSF IACUC committee. Protocols for human sample collection and analysis were approved by UCSF, and all analyses of human data were carried out in compliance with the relevant ethical regulations.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The sequencing data of the manuscript can be accessed using the following accession number: GSE105147. 
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Data analysis FlowJo v10.2 for flow cytometry analysis; ImageJ for immunofluorescence intensity quantification; Excel and Prism 6 for data analysis; Burrows-Wheeler Aligner (BWA), RSEM, Bowtie2, limma package, Integrative Genomics Viewer (IGV), ClueGO, and STRING v10.0 were used for RNA-seq and ribosome profiling analysis.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Validation These antibodies were validated by the vendor or published studies using either knockout or knockdown/overexpression immunofluorescence, flow cytometry and immunoblot assays.
Eukaryotic cell lines Policy information about cell lines
Cell line source(s)
We used mouse hepatocarcinoma cell lines generated from genetically engineered mouse (GEM) models and SNU-449 liver cancer cell line (ATCC® CRL-2234™) in this study.
Authentication
The SNU-449 have not been authenticated by our lab independently of ATCC's authentication. We authenticated the mouse HCC cell lines generated from GEMs by genotyping using both PCR, Western Blot and Immunofluorescence assays to detect the expression of MYC, KRASG12D, GFP and HA, etc. PD-L1 5'UTR CRISPR mutation cell lines were genotyped by PCR followed by sequencing.
Mycoplasma contamination
All cell lines were tested and are free of mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Research animals
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Animals/animal-derived materials
In this study, we developed genetically engineered mouse (GEM) models in C57/BL6 mouse strain. Data were generated from both male and female mice. For the orthotopic mouse model, male C57/BL6 mice and male athymic nude mice aged between 4-6 weeks, weight between 18-25g (median weight: 22g) were used.
Human research participants
Policy information about studies involving human research participants
Population characteristics
The patients' median age was 67.5 (17-84). The gender distribution was 8 female and 28 male. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Cultured cell lines were detached and harvested with 1X citric saline. Primary hepatocytes were harvested from mice and prepared with a liver dissociation kit (Miltenyi Biotech, 130-105-807) according to the manufacturer's instructions. Cell population abundance After antibody staining of single cells, FSC -SSC gating was used to determine pure live cell population to be analyzed.
Gating strategy
After live cell gating, PD-L1 positive cell populations were determined based on PD-L1 FMO control. The detailed gating strategy of immune profiling is described in Supplementary Figure 1. 
